Kalaris Therapeutics, Inc. (KLRS)
2.22
-0.04
(-1.77%)
USD |
NASDAQ |
Oct 13, 12:38
Kalaris Therapeutics Net Income (Quarterly) : -11.52M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -11.52M |
| March 31, 2026 | -10.86M |
| December 31, 2025 | -9.998M |
| September 30, 2025 | -11.89M |
| June 30, 2025 | -11.35M |
| March 31, 2025 | -10.20M |
| December 31, 2024 | -22.03M |
| September 30, 2024 | -38.08M |
| June 30, 2024 | -5.65M |
| March 31, 2024 | -3.407M |
| December 31, 2023 | -59.70M |
| September 30, 2023 | -44.27M |
| June 30, 2023 | -45.27M |
| March 31, 2023 | -41.18M |
| December 31, 2022 | -38.14M |
| Date | Value |
|---|---|
| September 30, 2022 | -42.07M |
| June 30, 2022 | -44.64M |
| March 31, 2022 | -43.86M |
| December 31, 2021 | -57.94M |
| September 30, 2021 | -45.51M |
| June 30, 2021 | -37.59M |
| March 31, 2021 | -30.92M |
| December 31, 2020 | -25.20M |
| September 30, 2020 | -23.61M |
| June 30, 2020 | -11.63M |
| March 31, 2020 | -9.339M |
| December 31, 2019 | -8.743M |
| September 30, 2019 | -7.27M |
| June 30, 2019 | -5.302M |
| March 31, 2019 | -2.524M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Replimune Group, Inc. | -69.77M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 11.52M |
| EPS Diluted (Quarterly) | -0.4839 |
| Enterprise Value | -38.34M |
| Earnings Yield | -90.73% |
| Normalized Earnings Yield | -90.72 |